• 1
    Haynes RB, Ackloo E, Sahota N et al. Interventions for enhancing medication adherence. Cochrane Database of Systematic Reviews 2008:CD000011.
  • 2
    Lora A, Kohn R, Levav I et al. Service availability and utilization and treatment gap for schizophrenic disorders: a survey in 50 low- and middle-income countries. Bull World Health Organ 2012;90:47-54B.
  • 3
    Large M, Farooq S, Nielssen O. Duration of untreated psychosis in low and middle income economies: the relationship between GDP and DUP. Br J Psychiatry 2008;193:272-8.
  • 4
    World Health Organization. Stop tuberculosis initiative.
  • 5
    Farooq S. Early intervention for psychosis in low and middle income (LAMI) countries needs a public health approach. Br J Psychiatry 2013;202:168-9.
  • 6
    Farooq S, Nazar Z, Irfan M et al. Schizophrenia treatment adherence in resource poor setting: randomised controlled trial of Supervised Treatment in Outpatients for Schizophrenia (STOPS). Br J Psychiatry 2011;199:467-72.
  • 7
    Kinon BJ, Liu-Seifert H, Adams DH et al. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia. J Clin Psychopharmacol 2006;26:632-7.
  • 8
    Perkins DO, Gu H, Weiden PJ et al. Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. J Clin Psychiatry 2008;69:106-13.
  • 9
    Weinmann S, Janssen B, Gaebel W. Guideline adherence in medication management of psychotic disorders: an observational multisite hospital study. Acta Psychiatr Scand 2005;112:18-25.